Editor's Note:
April's most popular stories show that our readers continue to be focused on mergers and acquisitions. While the rise of private equity continues to be a massive story in cardiology, leading to more coverage in April than any previous month, it was news of a potential industry-shifting deal by Boston Scientific that received the most attention.
On the technology side of things, a team of structural heart specialists made history by performing TTVR with a new valve. Will we learn more about this procedure in the months ahead? Watch this space to find out. Thank you for reading. - Michael Walter | Editor
Editor's Note:
April's most popular stories show that our readers continue to be focused on mergers and acquisitions. While the rise of private equity continues to be a massive story in cardiology, leading to more coverage in April than any previous month, it was news of a potential industry-shifting deal by Boston Scientific that received the most attention.
On the technology side of things, a team of structural heart specialists made history by performing TTVR with a new valve. Will we learn more about this procedure in the months ahead? Watch this space to find out. Thank you for reading. - Michael Walter | Editor